Medical Oncologist
Netherlands Cancer Institute/ Antoni van Leeuwenhoek
Amsterdam, Noord-Holland, Netherlands
Neeltje Steeghs, M.D., Ph.D. is a licensed Medical Oncologist and Clinical Pharmacologist. She served as chair of the Dutch Pharmacology Oncology Group and chair of the Dutch GIST consortium. Her main scientific interests are new drug development, including the performance of clinical phase I and early phase II trials, and the inclusion of pharmacokinetics and pharmacodynamics in these studies. She also has a major interest in the design aspects of early clinical studies.
Besides her clinical activities, she has been Clinical Assessor for the Medicines Evaluation Board of the European Medicines Agency (2009-2011), chair of the Dutch Sarcoma Study Group, board member for the Paediatric Oncology Research Foundation (2010-2013), Young investigator for the EORTC Soft Tissue and Bone Sarcoma Group (2013-2016), chair of the multidisciplinary expert board for the Center for Personalized Cancer Treatment (2012-2015) and Vice-Chair of the Medical Ethical Committee of the Netherlands Cancer Institute. She has also been board member for the Dutch Oncological Medicine Evaluation Board, the National Working Party for Cancer Drugs Interactions and the Translational Research Board of the Netherlands Cancer Institute. She has a.o. been editor of Gastrointestinal Stromal Tumor (GIST), and Pharmacology of Anti-Cancer Drugs.
She currently serves as the Director of Phase I studies and Clinical Research at the Netherlands Cancer Institute, in Amsterdam, the Netherlands and as advisor for several pharmaceutical companies.
Neeltje Steeghs has been principle investigator for many investigator initiated and industry sponsored clinical trials. She is regarded as a leading authority on mechanisms for safe and effective dosing of anticancer agents. She has authored or co-authored over 150 scientific papers, and has given numerous lectures on a variety of topics at international meetings.
Neeltje Steeghs was invited to join the ESMO 2024 Scientific Committee as member of the Developmental therapeutics track.
Disclosure information not submitted.
